Drugs / NCX4016
NCX4016
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00331786 | Jul 2006 → ? | colorectal cancer | Stony Brook University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00157508 | Mar 2003 → Aug 2004 | diabetic kidney disease, type 2 diabetes mellitus | Mario Negri Institute for Pharmacological Research | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01256775 Comparator | Sep 2003 → Apr 2005 | intermittent vascular claudication | NicOx Research Institute S.r.l. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NCX 4016 | “We wished to assess whether the prolonged administration of a NO-donating agent (NCX 4016) improves the functional capacity of PAD patients and affects the progression of...” NCT01256775 ↗3“NCX4016, a NO-releasing derivative of acetylsalicilic acid, has been shown to retain the analgesic, anti-inflammatory and antithrombotic activity of aspirin, but with less...” NCT00157508 ↗ “Phase I Multiple-Dose Safety, Pharmacokinetic and Pharmacodynamic Clinical Study of Nitric Oxide Releasing Aspirin (NCX 4016)” NCT00331786 ↗ “NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.” NCT01256775 ↗ |
| Known as | Nitric Oxide Releasing Aspirin | “Phase I Multiple-Dose Safety, Pharmacokinetic and Pharmacodynamic Clinical Study of Nitric Oxide Releasing Aspirin (NCX 4016)” NCT00331786 ↗ |
| Known as | Nitro-aspirin | “NCX4016 (Nitro-aspirin), a acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester of acetylsalicylic acid, is one of these novel compounds developed with the dual aim to expand the...” NCT00157508 ↗ |
| Action | Inhibit | “NCX4016 inhibits cyclooxygenase (COX) activity in platelets both in vitro and ex vivo” NCT00157508 ↗ |
| Modality | Other / unclassified | “NO-donating agent (NCX 4016)” NCT01256775 ↗ |
| Route | Oral | “Patients receive oral nitric oxide-releasing acetylsalicyclic acid twice daily for 6 months.” NCT00331786 ↗ |